Yayın:
KANSER TEDAVİSİNDE mTOR İNHİBİTÖRLERİ

Sadeleştirilmiş öğe sayfası
dc.contributor.authorÖzcan, Özge
dc.contributor.authorDikmen, Miriş
dc.contributor.orcid0009-0000-1090-0166
dc.date.accessioned2025-11-13T11:01:01Z
dc.date.issued2015-04-20
dc.identifier.doihttps://doi.org/10.12991/mpj.201519394607
dc.identifier.endpage290
dc.identifier.issn1309-0801
dc.identifier.issue3
dc.identifier.openalexW2162787000
dc.identifier.startpage290
dc.identifier.urihttps://hdl.handle.net/11421/5958
dc.identifier.urihttps://doi.org/10.12991/mpj.201519394607
dc.identifier.volume19
dc.language.isohu
dc.relation.ispartofMARMARA PHARMACEUTCAL JOURNAL
dc.rightsrestrictedAccess
dc.subjectPI3K/AKT/mTOR pathway
dc.subjectTemsirolimus
dc.subjectEverolimus
dc.subjectDiscovery and development of mTOR inhibitors
dc.subjectMedicine
dc.subjectChemistry
dc.subjectOncology
dc.subjectSignal transduction
dc.subjectBiochemistry
dc.subject.sdg3
dc.titleKANSER TEDAVİSİNDE mTOR İNHİBİTÖRLERİ
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5111839619
local.authorid.openalexA5042645402

Dosyalar

Koleksiyonlar

Publications